AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Longhorn Vaccines & Diagnostics to Present at The 50th Union World Conference on Lung Health

October 23, 2019

BETHESDA, Md.--(BUSINESS WIRE)--Oct 23, 2019--

Longhorn Vaccines & Diagnostics an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, will be participating and presenting scientific data at The 50 th Union World Conference on Lung Health on October 30 – November 2 in Hyderabad, India. The conference is the largest gathering of clinicians and public health workers, health program managers, policymakers, researchers and advocates working to end the suffering caused by lung disease with a focus specifically on the challenges faced by low-and lower-middle income populations.

Longhorn Vaccines and Diagnostics executive team will lead the following oral abstract session:

Title: Targeted Next-Generation Sequencing Methodology for Characterizing High-Prevalence Multi-Drug Resistance Mycobacterium tuberculosis Mutations
Speaker: Luke T. Daum, Ph.D., Chief Scientific Officer, Longhorn Vaccines & Diagnostics
Date & Time: Friday, November 1 at 10:30 am IST
Location: MR 1.03 & 1.04

About Longhorn Vaccines and Diagnostics

Longhorn Vaccines & Diagnostics is an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations. Longhorn’s core product, PrimeStore ® Molecular Transport Medium (MTM), is a patented, FDA approved, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations and drug manufacturers improve the diagnosis and treatment of infectious diseases such as mycobacterium tuberculosis (TB) and Influenza. Unlike standard devices for collecting and transporting TB samples, MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Longhorn is based in Bethesda, Maryland.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191023005255/en/

CONTACT: Media:

Sean Leous

Westwicke/ICR PR

Phone: +1.646.677.1839

sean.leous@icrinc.com

KEYWORD: MARYLAND UNITED STATES INDIA NORTH AMERICA ASIA PACIFIC

INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Longhorn Vaccines & Diagnostics

Copyright Business Wire 2019.

PUB: 10/23/2019 10:00 AM/DISC: 10/23/2019 10:01 AM

http://www.businesswire.com/news/home/20191023005255/en